Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair
Researchers across the field, from Duke University to Mayo Clinic, are increasingly focused on restoring damaged cartilage rather than simply managing the symptoms associated with its loss. Regentis Biomaterials’ GelrinC is designed to support the body’s natural cartilage-regeneration process through a gradual, controlled repair environment. Early clinical data has provided encouraging evidence for GelrinC, which already has approval in Europe, while an FDA-authorized pivotal trial is advancing its development toward potential U.S. approval. A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly,…